RenovoRx is trying to prove that an already-cleared oncology catheter can become a self-funding franchise before the Phase III survival readout arrives. For years the equity traded as a binary pancreatic-cancer option. The second-quarter print is the first stretch where device sales, site activations, and repeat orders look capable of carrying a commercial thesis on their own. That shift matters because the drug-device trial does not produce topline data until late next year, and the cash balance cannot wait on a single survival curve.
The commercial engine is still small, but the shape of the print is what changes the debate. Revenue reached $909 thousand and more than doubled the year-ago quarter. Sequential growth ran well ahead of the first-quarter step-up, and management raised full-year guidance after the first half already covered more than the entire prior year. Gross margin stayed in the mid-eighties, which is the economics of a disposable catheter rather than a drug launch. The offset sits in selling costs, which nearly doubled as the company staffed a lean commercial team. Net loss barely moved even as sales accelerated, which is the honest read on how early this ramp still is.
The forward question is whether twenty-one paying cancer centers can become a run-rate that funds operations before cash and warrant math force another raise. Management frames cash-flow break-even around a five-million quarterly sales pace and an internal plan that points to late next year. Nasdaq closed the bid-price matter in August after the shares held above the one-dollar floor, removing the immediate listing overhang. The equity at a mid-one-dollar handle and a mid-seventy-million capitalization is no longer pricing a pre-revenue option, but it is also not yet pricing a finished device company.